Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer

International Journal of Cardiovascular Imaging

Volumn 26, Issue 2, 2010, Pages 217-223

  Appel, Jon M ^a   Jensen, Benny V ^a   Nielsen, Dorte L ^a   Ryberg, Marianne ^a   Zerahn, Bo ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anthracyclines; Cardiotoxicity; Diastolic function; Epirubicin; Heart failure

Indexed keywords

EPIRUBICIN;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CARDIAC GATED IMAGING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MULTIPLE GATED ACQUISITION SCAN; PROGNOSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ANTIBIOTICS, ANTINEOPLASTIC; BLOOD PRESSURE; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; GATED BLOOD-POOL IMAGING; HEART FAILURE; HEART VENTRICLES; HUMANS; KAPLAN-MEIERS ESTIMATE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SYSTOLE; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 77950922395     PISSN: 15695794     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10554-009-9518-2     Document Type: Article

References (32)

1. SM Swain FS Whaley MS Ewer 2003 Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 11 2869 2879 10.1002/cncr.11407 1:CAS:528:DC%2BD3sXkslWrsLs%3D 12767102 (Pubitemid 36605157)
2. JM Appel D Nielsen B Zerahn BV Jensen K Skagen 2007 Anthracycline-induced chronic cardiotoxicity and heart failure Acta Oncol 46 5 576 580 10.1080/02841860601156165 1:CAS:528:DC%2BD2sXmtlWms7k%3D 17562433 (Pubitemid 46911916)
3. DD Von Hoff MW Layard P Basa HL Davis Jr AL Von Hoff M Rozencweig FM Muggia 1979 Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 5 710 717 (Pubitemid 10218041)
4. MF Xu PL Tang ZM Qian M Ashraf 2001 Effects by doxorubicin on the myocardium are mediated by oxygen free radicals Life Sci 68 8 889 901 10.1016/S0024-3205(00)00990-5 1:CAS:528:DC%2BD3MXlvFKrsQ%3D%3D 11213359 (Pubitemid 32168065)
5. PV Escriba M Sastre JA Garcia-Sevilla 1995 Disruption of cellular signalling pathways by daunomycin through destabilization of non lamellar membrane structures Proc Natl Acad Sci USA 92 16 7595 7599 10.1073/pnas.92.16. 7595 1:CAS:528:DyaK2MXntlKls7s%3D 7638236
6. S Zhou A Starkov MK Froberg RL Leino KB Wallace 2001 Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin Cancer Res 61 2 771 777 1:CAS:528:DC%2BD3MXht1Gmt7o%3D 11212281 (Pubitemid 32128645)
7. M Tokarska-Schlattner M Zaugg C Zuppinger T Wallimann U Schlattner 2006 New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics J Mol Cell Cardiol 41 3 389 405 10.1016/j.yjmcc.2006.06.009 1:CAS:528:DC%2BD28Xps1Olu7w%3D 16879835 (Pubitemid 44362995)
8. VI Kapelko CP Williams DE Gutstein JP Morgan 1996 Abnormal myocardial calcium handling in the early stage of adriamycin cardiomyopathy Arch Physiol Biochem 104 2 185 191 10.1076/apab.104.2.185.12881 1:CAS:528:DyaK28Xkt1Cksr8%3D 8818203 (Pubitemid 26229314)
9. Early Breast Cancer Trialists' Collaborative Group 1998 Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 9132 930 942 10.1016/S0140-6736(98)03301-7 (Pubitemid 28427277)
10. IC Henderson GP Canellos 1980 Cancer of the breast: the past decade (second of two parts) N Engl J Med 302 2 78 90 1:STN:280:DyaL3c%2Fnsl2guw%3D%3D 7350436 (Pubitemid 10210623)
11. M Ryberg D Nielsen T Skovsgaard J Hansen BV Jensen P Dombernowsky 1998 Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer J Clin Oncol 16 11 3502 3508 1:CAS:528:DyaK1cXnsVOgtrs%3D 9817267
12. EA Lefrak J Pitha S Rosenheim JA Gottlieb 1973 A clinicopathologic analysis of adriamycin cardiotoxicity Cancer 32 2 302 314 10.1002/1097- 0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2 1:STN:280: DyaE3s3jtVWquw%3D%3D 4353012
13. JL Ritchie TM Bateman RO Bonow MH Crawford RJ Gibbons RJ Hall RA O'Rourke AF Parisi MS Verani 1995 Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology J Am Coll Cardiol 25 2 521 547 10.1016/0735-1097(95)90027-6 1:STN:280:DyaK2M7jtVyrtw%3D%3D 7829809
14. LJ Steinherz T Graham R Hurwitz HM Sondheimer RG Schwartz EM Shaffer G Sandor L Benson R Williams 1992 Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the children's cancer study group Pediatrics 89 5 Pt 1 942 949 1:STN:280:DyaK383ltlaqtQ%3D%3D 1579408
15. J Alexander N Dainiak HJ Berger L Goldman D Johnstone L Reduto T Duffy P Schwartz A Gottschalk BL Zaret 1979 Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography N Engl J Med 300 6 278 283 1:STN:280:DyaE1M%2Fptlymtw%3D%3D 759880
16. M Belham A Kruger S Mepham G Faganello C Pritchard 2007 Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy Eur J Heart Fail 9 4 409 414 10.1016/j.ejheart.2006.09.007 1:CAS:528: DC%2BD2sXjsVeqsrg%3D 17067854 (Pubitemid 46441967)
17. I Mitani D Jain TM Joska B Burtness BL Zaret 2003 Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era J Nucl Cardiol 10 2 132 139 10.1067/mnc.2003.7 12673177 (Pubitemid 36503798)
18. BV Jensen T Skovsgaard SL Nielsen 2002 Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients Ann Oncol 13 5 699 709 10.1093/annonc/mdf132 1:STN:280:DC%2BD38zjtlWrsw%3D%3D 12075737 (Pubitemid 34567375)
19. J Ganame P Claus B Eyskens A Uyttebroeck M Renard J D'hooge M Gewillig B Bijnens GR Sutherland L Mertens 2007 Acute cardiac functional and morphological changes after anthracycline infusions in children Am J Cardiol 99 7 974 977 10.1016/j.amjcard.2006.10.063 1:CAS:528:DC%2BD2sXjslSmt7g%3D 17398195 (Pubitemid 46483288)
20. J Suzuki A Yanagisawa T Shigeyama J Tsubota T Yasumura K Shimoyama K Ishikawa 1999 Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography Angiology 50 1 37 45 10.1177/000331979905000105 1:STN:280:DyaK1M7it1aktw%3D%3D 9924887
21. K Schmitt G Tulzer M Merl G Aichhorn A Grillenberger G Wiesinger G Hofstadler 1995 Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: diastolic versus systolic parameters Eur J Pediatr 154 3 201 204 10.1007/BF01954271 1:STN:280:DyaK2M3nvVaktg%3D%3D 7758517
22. AC Nagy E Tolnay T Nagykalnai T Forster 2006 Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI Neoplasma 53 6 511 517 1:CAS:528:DC%2BD2sXhsVOlsbw%3D 17167721
23. P Lu 2005 Monitoring cardiac function in patients receiving doxorubicin Semin Nucl Med 35 3 197 201 10.1053/j.semnuclmed.2005.02.005 16098293 (Pubitemid 41138138)
24. IP Clements LJ Sinak RJ Gibbons ML Brown MK O'Connor 1990 Determination of diastolic function by radionuclide ventriculography Mayo Clin Proc 65 7 1007 1019 1:STN:280:DyaK3czjtFCrsQ%3D%3D 2198392
25. LJ Steinherz PG Steinherz CT Tan G Heller ML Murphy 1991 Cardiac toxicity 4 to 20 years after completing anthracycline therapy JAMA 266 12 1672 1677 10.1001/jama.266.12.1672 1:STN:280:DyaK3MzlvFequg%3D%3D 1886191
26. MT Meinardi DJ van Veldhuisen JA Gietema WV Dolsma F Boomsma MP van den Berg C Volkers J Haaksma EG de Vries DT Sleijfer WT van der Graaf 2001 Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and loco regional radiotherapy in breast cancer patients J Clin Oncol 19 10 2746 2753 1:CAS:528:DC%2BD3MXkt1Omu7c%3D 11352968
27. HJ Muntinga F van den Berg HR Knol MG Niemeyer PK Blanksma H Louwes EE van der Wall 1997 Normal values and reproducibility of left ventricular filling parameters by radionuclide angiography Int J Card Imaging 13 2 165 171 10.1023/A:1005704415207 1:STN:280:DyaK2s3msVelsQ%3D%3D 9110196 (discussion 173) (Pubitemid 27130279)
28. SP Schulman EG Lakatta JL Fleg L Lakatta LC Becker G Gerstenblith 1992 Age-related decline in left ventricular filling at rest and exercise Am J Physiol 263 6 Pt 2 H1932 H1938 1:STN:280:DyaK3s7ivVGisg%3D%3D 1362335
29. LC Kremer EC van Dalen M Offringa J Ottenkamp PA Voute 2001 Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study J Clin Oncol 19 1 191 196 1:CAS:528: DC%2BD3MXot1Wguw%3D%3D 11134212
30. M Ryberg D Nielsen G Cortese G Nielsen T Skovsgaard PK Andersen 2008 New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients J Natl Cancer Inst 100 15 1058 1067 10.1093/jnci/djn206 1:CAS:528:DC%2BD1cXpslWktrg%3D 18664656
31. RO Bonow 1991 Radionuclide angiographic evaluation of left ventricular diastolic function Circulation 84 3 Suppl I208 I215 1:STN:280: DyaK3Mzls1Kruw%3D%3D 1884488
32. JJ Doyle AI Neugut JS Jacobson VR Grann DL Hershman 2005 Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study J Clin Oncol 23 34 8597 8605 10.1200/JCO.2005.02.5841 16314622 (Pubitemid 46211501)